MarketMoodz
Alpha Tau Medical stock jumps on Alpha DaRT interim glioblastoma data
Alpha Tau Medical shares jumped about 20% after interim REGAIN results showed early activity for Alpha DaRT in recurrent glioblastoma, with the stock hovering around $10.25 intraday. In a three-patient cohort, two complete responses and a 30% tumor reduction were observed, and no unanticipated safety events were reported.
Key Takeaways
- Shares rose about 20.4% to $10.25 intraday after REGAIN interim results in recurrent glioblastoma.
- Two patients achieved complete responses with no enhancing tumor lesions; one patient showed about 30% tumor reduction.
- No unanticipated serious adverse events; one grade 3 event (seizure with temporary paralysis) resolved with steroids.
- Interim data are from a three-patient cohort, a small sample size that may not translate to larger studies.
- Alpha Tau completed enrollment in the ReSTART pivotal trial for recurrent cutaneous squamous cell carcinoma.
People Involved
- No specific individuals mentioned
Entities Involved
- Alpha Tau Medical Ltd (DRTS)Biotech company developing Alpha DaRT technology
- Alpha DaRTAlpha radiation brachytherapy modality used in trials
- REGAIN studyU.S. safety/feasibility trial in recurrent glioblastoma
- ReSTART trialPivotal trial for recurrent cutaneous squamous cell carcinoma
MarketMoodz Analysis
The interim REGAIN results suggest early activity for Alpha DaRT in a difficult-to-treat disease and could add near-term upside to Alpha Tau’s valuation if confirmed in larger cohorts. Investors will be watching for readouts from additional patients and longer follow-up to assess durability of responses and any late safety signals.
Historically, many radiotherapy–based approaches show initial promise in small cohorts but fail to scale in larger trials. The quick move in DRTS stock reflects a risk-on stance around potential catalysts, but the pathway to approval remains uncertain. Next catalysts include additional REGAIN data, longer-term safety updates, and the ReSTART readouts that could unlock partnerships or licensing deals.
Source: Original Article